Acrivon Therapeutics (ACRV) CAO reports 99-share tax withholding on RSU vesting

Rhea-AI Filing Summary

Acrivon Therapeutics Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition. On the vesting of restricted stock units, 99 shares of common stock were withheld by the company at a value of $1.92 per share to cover mandatory tax withholding. After this non-market transaction, she directly holds 3,907 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peterson Katharine

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	99	$1.92	$190.08

Holdings After Transaction: Common Stock — 3,907 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 99 shares Per-share value for withholding: $1.92 per share Shares owned after transaction: 3,907 shares +1 more

4 metrics

Shares withheld for taxes 99 shares Withheld to satisfy mandatory tax withholding on RSU vesting

Per-share value for withholding $1.92 per share Value used for 99-share tax-withholding disposition

Shares owned after transaction 3,907 shares Directly held Acrivon Therapeutics common stock following Form 4 event

Tax-withholding share count 99 shares Also reported in transactionSummary as taxWithholdingShares

Key Terms

restricted stock units, mandatory tax withholding, Form 4

3 terms

restricted stock units financial

"upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding financial

"to satisfy the mandatory tax withholding requirement"

Form 4 regulatory

"reported on a Form 4 insider filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Katharine

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		F(1)		99	D	$1.92	3,907	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Katharine Peterson?

Acrivon Therapeutics reported that Chief Accounting Officer Katharine Peterson had 99 common shares withheld to satisfy tax obligations on vested restricted stock units. This was a non-open-market tax-withholding disposition reported on a Form 4 insider filing.

Was the ACRV insider transaction a market sale of shares?

No, the transaction was not an open-market sale. The 99 Acrivon Therapeutics shares were withheld by the company to cover mandatory tax withholding triggered when restricted stock units vested, according to the Form 4 footnote disclosure.

At what price were the withheld Acrivon Therapeutics shares valued?

The 99 Acrivon Therapeutics common shares withheld for tax purposes were valued at $1.92 per share. This value is used for the tax-withholding disposition recorded in the Form 4 filed for Chief Accounting Officer Katharine Peterson.

How many ACRV shares does Katharine Peterson hold after this Form 4 transaction?

Following the tax-withholding disposition, Katharine Peterson directly holds 3,907 shares of Acrivon Therapeutics common stock. This post-transaction balance is disclosed in the Form 4 as the total shares beneficially owned after the reported event.

What triggered the tax-withholding share disposition for Acrivon Therapeutics (ACRV)?

The disposition was triggered when restricted stock units vested, creating a tax obligation. To satisfy mandatory withholding, Acrivon Therapeutics withheld 99 common shares from Chief Accounting Officer Katharine Peterson instead of requiring a separate cash payment.